Abeona Therapeutics ABEO Insider Ownership

Updated Oct 21, 2026

Over the trailing 12 months, ABEO insiders sold $3.57 million worth of shares (638.39K shares) in open-market trades, with no open-market purchases.

• By number of insiders, Abeona Therapeutics saw 9 insiders sell on the open market over the past 12 months and none buy.
• The largest open-market sales of ABEO in the past 12 months were by Vishwas Seshadri (Chief Executive Officer), totaling $1.51 million (268.74K shares), most recently on September 29, 2026.
• Away from the open market, ABEO insiders received 759.65K shares in stock awards and gave away 500 shares as gifts over the last 12 months.
• According to Business Quant data, insiders at Abeona Therapeutics reported 3.54Mn shares in total in their latest Form 4 filings, down 4.70% from 3.71Mn shares at the end of Q2 2026 and up 21.93% from 2.9Mn shares at the end of Q3 2025.
• By type of ownership, ABEO insiders hold all of their 3.54Mn shares directly.
• Business Quant counts 13 insiders with holdings in Abeona Therapeutics stock, among the officers, directors and 10% owners who have filed a Form 4 in the past two years.
• Abeona Therapeutics' three largest insider shareholders, based on their latest Form 4 filings, are Vishwas Seshadri (Chief Executive Officer, 1.29Mn shares), Joseph Walter Vazzano (Chief Financial Officer, 482.89K shares) and Brendan M. O'Malley (SVP, Chief Legal Officer, 421.23K shares).
• Vishwas Seshadri alone accounts for 36.37% of the shares held by Abeona Therapeutics insiders.
• Institutional investors held 68.82% of Abeona Therapeutics stock at the end of Q2 2026, while the latest Form 4 filings of its insiders account for about 6.18%; other investors, including the public, hold roughly 25.00%.
• Over the trailing 12 months, 13 insiders reported transactions in ABEO stock across 47 Form 4 filings.
• The insider data for ABEO reflects Form 4 filings through September 29, 2026.